Please login to the form below

Not currently logged in
Email:
Password:

Juno Therapeutics

This page shows the latest Juno Therapeutics news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

The company has responded to the difficult period with the $9bn acquisitions of Juno Therapeutics - giving it a stake in the emerging CAR-T cancer immunotherapy market - as well as paying

Latest news

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    Celgene has agreed to acquire the 90% of CAR-T specialist Juno Therapeutics it doesn’t already own in a $9bn deal that, at a stroke, makes it a big player ... If that prediction comes true, the price tag for Juno looks like a bargain.

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    Is acquisitive Celgene now eyeing CAR-T specialist Juno? Rumours circulate just days after the US biotech confirms ImpactBio purchase. ... Celgene is in talks with Juno Therapeutics about a possible takeover deal, right after cutting a $7bn deal to buy

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    What happens next for Cellectis is hard to gauge. Another CAR-T developer - Juno Therapeutics - had its lead therapy JCAR015 placed under a clinical hold by the FDA after a patient

  • Intriguing data with Juno's new CAR-T therapy Intriguing data with Juno's new CAR-T therapy

    Intriguing data with Juno's new CAR-T therapy. Suggests a long treatment effect from the biotech's JCAR017 candidate. ... CAR-T developer Juno Therapeutics has reported data suggesting the benefits of this type of cancer immunotherapy could extend long

  • Kite files first CAR-T candidate in Europe Kite files first CAR-T candidate in Europe

    Side effects have already claimed one pipeline casualty, with Juno Therapeutics giving up on its lead candidate JCAR015 earlier this year after patient deaths in trials.

More from news
Approximately 7 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Pharma deals in July 2015 Pharma deals in July 2015

    It still sounds like a high price but perhaps it is in Celgene'sDNA because only a month ago it bought shares in Juno Therapeutics at over a 100% premium in

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration

  • Pharma deals in May 2015 Pharma deals in May 2015

    Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... 900. Editas/Juno Therapeutics. Collaboration. Development of next generation CAR-T

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Juno Therapeutics names Cindy Elkins as CIO Juno Therapeutics names Cindy Elkins as CIO

    Juno Therapeutics names Cindy Elkins as CIO. She joins the biopharma from Genentech, where she was VP of IT. ... Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics